Title
Category
Credits
Event date
Cost
  • Oncology
  • AMA PRA Category 1 Credit™
$0.00
  • Psychiatry
  • AANP Contact Hours
  • AMA PRA Category 1 Credit™
  • ANCC
  • Participation
$0.00
The rapid onset of COVID-19 in the United States, combined with the dismantling of the spring 2020 medical conference infrastructure and widespread travel bans and social distancing has created a synchronous need in all clinical arenas to manage patients with pre-existing conditions, such as schizophrenia, who require management with LAIs. Join our expert faculty for this on-demand online activity, focusing on their expert insights into guiding patients, caregivers, and clinicians on using LAIs during the global health pandemic of COVID-19.
  • Psychiatry
  • AANP Contact Hours
  • AMA PRA Category 1 Credit™
  • ANCC
  • Participation
$0.00
​​​​​​Join Drs Les Citrome, Steve Stoner, and Board Certified Family Psychiatric Nurse Practitioner Tory Woodward for this on-demand online activity, as they discuss considerations for implementing LAI clinics and best practices for communicating with patients, caregivers, and clinicians regarding the use of LAIs during the global health pandemic of COVID-19.  This activity is supported by an educational grant from Alkermes.
  • Psychiatry
  • AANP Contact Hours
  • AMA PRA Category 1 Credit™
  • ANCC
  • Participation
$0.00
In recent years, overwhelming evidence suggests that LAIs may improve adherence, reduce relapse and hospitalizations, lessen the risk of treatment failure, and decrease mortality. Also, much evidence suggests the use of these treatments should no longer be reserved for last line, but offered at an earlier place in the illness. Moreover, new agents have arrived on the market which can be dosed without oral overlap, paving the way to less burdensome initiation strategies. Join Drs.
  • Oncology
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
Medical Moment Two: Expert Insight on Applying the ADAURA Results to Treatment of Early-Stage NSCLC Patients 
  • Oncology
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
Medical Moment One: Expert Insight on Practical Aspects of Molecular Profiling for Early-Stage NSCLC Cancers 
  • Oncology
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
The implementation of molecular testing, especially analysis of human epidermal growth factor receptor 2 (HER2) status, has had a significant impact on clinical practice and patient care. Join Drs. David Ilson and Michael Press for this on-demand online activity, as they discuss assessment of HER2-mutant disease from each of their unique perspectives.Supported through an independent educational grant from AstraZeneca and Daiichi Sankyo. 
  • Oncology
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
Antibody-drug conjugates or “ADCs” are a novel class of highly potent biopharmaceutical drug composed of an antibody linked, via a chemical linker, to a biologically active drug or cytotoxic compound. Nearly 150 investigational ADCs are currently in pre-clinical and clinical trials. Join Drs. David Ilson and Kohei Shitara as they discuss emerging data from select clinical trials evaluating combinations of HER2-targeted therapies for patients with gastric cancer.Supported through an independent educational grant from AstraZeneca and Daiichi Sankyo. 
  • Oncology
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
Clinicians must be aware and up-to-date on the most effective approaches to management in order to provide patients with the most appropriate course of therapy. Join Drs. David Ilson and Yelena Janjigian as they discuss the rapidly evolving landscape of gastric cancer treatment, focusing on available front- and subsequent-lines of treatment, and how to tailor treatment to patients based on health status, prior lines of therapy, cost, convenience and access to care, genetic aberrations, and availability of a clinical trial.

Pages